#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

आज हम बात करेंगे Ambalal Sarabhai Enterprises Company के Mohal Sarabhai से, कल कंपनी की ओर से अपडेट आया था। बता दें, Cosara Diagnostics को RT-PCR test kit के लिए License मिला है। बता दें, कंपनी को Dengue  RT-PCR test kit के लिए Manufacturing License मिला है। इसी पर करेंगे खास चर्चा, देखें वीडियो

Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Ambalal Sarabhai Enterprises के Mohal Sarabhai से खास बातचीत, जानें Company का Future Plan

CoSara is a joint venture company of Synbiotics Limited, a wholly owned subsidiary Ambalal Sarabhai Enterprises Limited and Co- Diagnostics Inc, USA.

Cosara Diagnostics gets CDSCO license to manufacture SARAGENE Dengue Test Kit

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

आज हम बात करेंगे Ambalal Sarabhai Enterprises Company के Mohal Sarabhai से, कल कंपनी की ओर से अपडेट आया था। बता दें, Cosara Diagnostics को RT-PCR test kit के लिए License मिला है। बता दें, कंपनी को Dengue  RT-PCR test kit के लिए Manufacturing License मिला है। इसी पर करेंगे खास चर्चा, देखें वीडियो


Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

KYC में Ambalal Sarabhai Enterprises का Management, Company के नए Plan पर चर्चा | CNBC Awaaz

Ambalal Sarabhai Enterprises consolidated net profit rises 2760.22% in the June 2021 quarter

Ambalal Sarabhai Enterprises consolidated net profit rises 20.84% in the March 2021 quarter

Ambalal Sarabhai Enterprises reports standalone net loss of Rs 8.93 crore in the March 2021 quarter

Ambalal Sarabhai Enterprises (ASE) hit an upper circuit of 20% at Rs 33.40 after the company said that its subsidiary has ramped up the production of API Amphotericin B.

Ambalal Sarabhai spurts after unit hikes production of Amphotericin B

Used in treatment of post-Covid infection

Ambalal Sarabhai Enterprises’ subsidiary ramps up production of Amphotericin B

CoSara Diagnostics gets a license for the manufacture and sale of SARAGENE Chikungunya Virus (CHIKV) Test Kit for diagnosis of Chikungunya Virus.

Ambalal Sarabhai Enterprises subsidiary’s JV gets CDSCO nod to manufacture CHIKV Test Kit; stock up 1%

BRIEF-Ambalal Sarabhai Enterprises -JV Gets CDSCO License To Manufacture Saragene Chikungunya Virus Test Kit

BRIEF-Ambalal Sarabhai Enterprises -JV Gets CDSCO License To Manufacture Saragene Chikungunya Virus Test Kit By Reuters

BRIEF-India’s Ambalal Sarabhai Enterprises Dec-Qtr Consol Net PAT Rises

Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Ambalal Sarabhai Enterprises Limited is a manufacturer of formulations. It markets specialty pharmaceutical products under its three sub-divisions: oncology, infertility and uro-gynaec.